Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia

American Journal of Hematology

Volumn 84, Issue 2, 2009, Pages 79-86

  Ayala, Rosa M ^a   Martínez López, Joaquín ^a   Albízua, Enriqueta ^a   Diez, Amalia ^b   Gilsanz, Florinda ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; ERYTHROID KRUPPEL LIKE FACTOR; HEMOGLOBIN; THROMBOPOIETIN RECEPTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; BONE MARROW CELL; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EVENT FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LYMPHOID TISSUE; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REMISSION; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; BONE MARROW; CHROMOSOME ABERRATIONS; DISEASE-FREE SURVIVAL; ERYTHROPOIESIS; GATA1 TRANSCRIPTION FACTOR; GATA2 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RECEPTORS, THROMBOPOIETIN; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 59949090392     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21332     Document Type: Article

References (65)

1. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993;81:2844-2853.
2. Tenen D. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003;3:89-101.
3. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997;278:1059-1064.
4. Speck N, Gilliland G. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002;2:502-513.
5. Yagi T, Morimoto A, Eguchi M, et al. Identification of a gene expressión signature associated with pediatric AML prognosis. Blood 2003;102:1849-1856.
6. Bullinger L, Döhner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004;350:1605-1616.
7. Grimwade D, Haferlach T. Gene-expression profiling in acute myeloid leukemia. N Engl J Med 2004;350:1676-1678.
8. Valk P, Verhaak R, Beijen M, Erpelinck Cea. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004;350:1617-1628.
9. Bouilloux F, Juban G, Cohet N, et al. EKLF restricts megakaryocytic differentiation at the benefit of erythrocytic differentiation. Blood 2008;112:576-584.
10. Löseke S, Grage-Griebenow E, Wagner A, et al. Differential expression of IFN-alfa subtypes in human PBMC: Evaluation of novel real-time PCR assays. J Immunol Methods 2003;276:207-222.
11. Ginzinger DG. Gene quantification using real-time quantitative PCR: An emerging technology hits the mainstream. Exp Hematol 2002;30:503-512.
12. Song W-J, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999;23:166-175.
13. Langabeer S, Gale R, Rollinson S, et al. Mutations of the AML 1 gene in acute myeloid leukemia of FAB types M0 and M7. Genes Chromosomes Cancer 2002;34:24-32.
14. Roumier C, Fenaux P, Lafage M, et al. New mechanisms of AML1 gene alteration in hematological malignancies. Leukemia 2003;17:9-16.
15. Bolufer P, Barragan E, Verdeguer A, et al. Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes. Haematologica 2002;87:23-32.
16. Weiss M, Orkin S. Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis. Proc Natl Acad Sci USA 1995;92:9623-9627.
17. McDevitt M, Fujiwara Y, Shivdasani R, Orkin S. An upstream, DNase I hypersensitive region of the hematopoietic-expressed transcription factor GATA-1 gene confers developmental specificity in transgenic mice. Proc Natl Acad Sci USA 1997;94:7976-7981.
18. Patmasiriwat P, Fraizer G, Kantarjian H, Saunders G. WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia 1999;13:891-900.
19. Shimamoto T, Ohyashiki K, Ohyashiki J, et al. The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia. Blood 1995;86:3173-3180.
20. Shimamoto T, Ohyashiki J, Ohyashiki K, et al. GATA-1, GATA-2, and stem cell leukemia gene expression in acute myeloid leukemia. Leukemia 1994;8:1176-1180.
21. Qian Z, Fernald AA, Godley LA, et al. Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy- related acute myeloid leukemia. Proc Natl Acad Sci USA 2002;99:14925-14930.
22. Wechsler J, Greene M, McDevitt M, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002;32:148-152.
23. Hitzler JK, Cheung J, Li Y, et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 2003;101:4301-4304.
24. Xu G, Nagano M, kanezaki R, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 2003;102:2960-2968.
25. Ohyashiki K, Ohyashiki J, Shimamoto T, Toyama K. Pattern of expression and their clinical implications of the GATA family, stem cell leukemia gene, and EVI1 in leukemia and myelodysplastic syndromes. Leuk Lymphoma 1996;23: 431-436 (Review).
26. Sposi NM, Zon LI, Care A, et al. Cell cycle-dependent initiation and lineage- dependent abrogation of GATA-1 expression in pure differentiating hematopoietic progenitors. Proc Natl Acad Sci USA 1992;89:6353-6357.
27. Tsai F, Browne C, Orkin S. Knock-in mutation of transcription factor GATA-3 into the GATA-1 locus: Partial rescue of GATA-1 loss of function in erythroid cells. Dev Biol 1998;196:218-227.
28. Wang L, Dong L, Liu G. GATA-2 gene expression in leukemia patients and its significance. Zhonghua Xue Ye Xue Za Zhi 2001;22:27-29.
29. Kumano K, Chiba S, Shimizu K, et al. Notch1 inhibits differentiation of hematopoietic cells by sustaining GATA-2 expression. Blood 2001;98:3283-3289.
30. Perkins A, Sharpe A, Orkin S. Lethal beta-thalassaemia in mice lacking the erythroid CACCC-transcription factor EKLF. Nature 1995;375:318-322.
31. Armstrong J, Emerson B. Transcription of chromatin: These are complex times. Curr Opin Genet Dev 1998;8:165-172.
32. Starck J, Cohet N, Gonnet C, et al. Functional cross-antagonism between transcription factors FLI-1 and EKLF. Mol Cell Biol 2003;23:1390-1402.
33. Deveaux S, Filipe A, Lemarchandel V, et al. Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes. Blood 1996;87:4678-4685.
34. Chelvatheebam S, Langabeer S, Linch D, et al. Incidence and prognostic significance of C-MPL expression in acute myeloid leukemia. Leuk Res 2003;27:869-870.
35. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999;94:3717-3721.
36. Schroder J, Kolkenbrock S, Tins J, et al. Analysis of thrombopoietin receptor (c-mpl) mRNA expression in de novo acute myeloid leukemia. Leuk Res 2000;24:401-409.
37. Vigon I, Dreyfus F, Melle J, et al. Expression of the c-mpl proto-oncogene in human hematologic malignancies. Blood 1993;82:877-883.
38. Albitar M, Manshouri T, Kantarjian H, et al. Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. Leuk Res 1999;23:63-69.
39. Wetzler M, Baer M, Bernstein S, et al. Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy. J Clin Oncol 1997;15:2262-2268.
40. Kaban K, Kantarjian H, Talpaz M, et al. Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: Correlation with disease progression and response to therapy. Cancer 2000;88:570-576.
41. Yoon S, Li C, Tefferi A. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: Immunoperoxidase staining patterns and clinical correlates. Eur J Haematol 2000;65:170-174.
42. Bullinger L, Rucker FG, Kurz S, et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007;110:1291-1300.
43. Bullinger L, Dohner K, Kranz R, et al. An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 2008;111:4490-4495.
44. Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1919-1928.
45. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 2005;106:3740-3746.
46. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-1918.
47. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA). Blood 2002;100:2717-2723.
48. Fröhling S, Schlenk R, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004;22:624-633.
49. Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004;103:1901-1908.
50. Fine B, Stanulla M, Schrappe M, Ho Mea. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood 2004;103:1043-1049.
51. Siehl J, Thiel E, Heufelder K, et al. Possible regulation of Wilms tumour gene1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias. Br J Haematol 2003;123:235-242.
52. Baldus CD, Liyanarachchi S, Mrozek K, et al. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci 2004;101:3915-3920.
53. Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS- related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: A cancer and leukemia group B study. J Clin Oncol 2005;23:9234-9242.
54. Baldus CD, Thiede C, Soucek S, et al. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: Prognostic implications. J Clin Oncol 2006;24:790-797.
55. Bienz M, Ludwig M, Mueller BU, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005;11:1416-1424.
56. Harris N, Jaffe E, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999;10:1419-1432.
57. Bennett J, Catovsky D, Daniel M, et al. Propolsals for the classification of acute leukaemias. French-American-British (FAB) Cooperative Group. Br J Haematol 1976;33:451-458.
58. Grimwade D, Walker H, Oliver Fea. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1.612 patients entered into MRC AML10 trial. Blood 1998;92:2322-2333.
59. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-1320.
60. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77:1666-1674.
61. Wolff SN, Herzig RH, Fay JW, et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remision: Long-term follow-up and results. J Clin Oncol 1989;9:1260-1267.
62. Sanz M, Martin G, González M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group. Blood 2004;103:1237-1243.
63. Kozu T. Junctions of the AML1/MTG8 (ETO) fusion are constant in t(8,21) acute myeloid leucemia detected by reverse transcription polymerase cam reaction. Blood 1993;82:1270-1276.
64. Gabert J. RQ-PCR for early diagnosis of relapse risk in leukemia (Europe Against Cancer Program). http://ifrjr.nord.univ-mrs.fr/mrd-leukemia (accessed March 2002).
65. Muller PY, Janovjak H, Miseret A, Dobbie Z. Processing of gene expresión data generated by quantitative real time RT-PCR. Biotechniques 2002;6:2-7.